IL1RN intron 2 polymorphism caused by variable number tandem repeats is associated with 1-year outcome in patients with ischaemic stroke

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 78, Issue 2, 2007, Pages 183-186

  Gromadzka, G ^a,b   Sarzynska Dlugosz, I ^b   Czlonkowska, A ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1 RECEPTOR;

ALLELE; ARTICLE; CEREBROVASCULAR ACCIDENT; CHROMOSOME 2; CONTROLLED STUDY; DISEASE SEVERITY; DNA POLYMORPHISM; FUNCTIONAL DISEASE; GENETIC ANALYSIS; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STROKE; SYMPTOMATOLOGY; TANDEM REPEAT; WORLD HEALTH ORGANIZATION;

BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; GENOTYPE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MINISATELLITE REPEATS; POLYMORPHISM, GENETIC; PROGNOSIS; TREATMENT OUTCOME;

EID: 33846856909     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2006.093104     Document Type: Article

References (23)

1. Chamorro A, Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 2006;37:291-3.
2. Zheng Z, Yenari MA. Post-ischemic inflammation: molecular mechanisms and therapeutic implications. Neurol Res 2004;26:884- 92.
3. Di Napoli M, Schwaninger M, Cappelli R, et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005;36:1316-29.
4. Członkowska A, Rygiewicz D, Lechowicz W. Basic analytical parameters as the predictive factors for 30-day case fatality rate in stroke. Acta Neurol Scand 1997;95:121-4.
5. Tarnacka B, Gromadzka G, Czlonkowska A. The markers of systemic inflammation in acute ischemic stroke. Central Eur J Immunol 1999;24:139-43.
6. Touzani O, Boutin H, Chuquet J, et al. Potential mechanisms of interleukin-1 involvement in cerebral ischaemia. J Neuroimmunol 1999;100:203-15.
7. Boutin H, LeFeuvre RA, Horai R, et al. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001;21:5528-34.
8. Emsley HC, Smith CJ, Georgiou RF, et al. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005;76:1360-72.
9. Danis VA, Millington M, Hyland VJ, et al. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-10.
10. Dewberry R, Holden H, Crossman D, et al. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2394-400.
11. Seripa D, Dobrina A, Margaglione M, et al. Relevance of interleukin-1 receptor antagonist intron-2 polymorphism in ischemic stroke. Cerebrovasc Dis 2003;15:276-81.
12. Lee BC, Ahn SY, Doo HK, et al. Susceptibility for ischemic stroke in Korean population is associated with polymorphisms of the interleukin-1 receptor antagonist and tumor necrosis factor-alpha genes, but not the interleukin-1beta gene. Neurosci Lett 2004;357:33-6.
13. World Health Organization. International classification of impairments, disabilities and handicaps. Geneva: WHO, 1980.
14. Foulkes M, Wolf P, Price T. Stroke Data Bank: design, methods, and baseline characteristic. Stroke 1988;19:547-54.
15. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
16. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in ischemic stroke-background and study protocol. Stroke 1985;16:885-90.
17. Mahoney FI, Barthel D. Functional evaluation: the Barthel Index. Maryland State Med J 1965;14:56-61.
18. Van Swieten JC, Koudstaal PJ, Visser MC. Intraobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-7.
19. Kantarci OH, Atkinson EJ, Hebrink DD, et al. Association of two variants in IL-1beta and IL-1 receptor antagonist genes with multiple sclerosis. J Neuroimmunol 2000;106:220-7.
20. Roberts L, Counsell C. Assessment of clinical outcomes in acute stroke trials. Stroke 1998;29:986-91.
21. Chamorro A, Horcajada JP, Obach V, et al. The Early Systemic Prophylaxis of Infection After Stroke Study: a randomized clinical trial. Stroke 2005;36:1495-500.
22. Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. Circulation 2004;109:2698-704.
23. Katabami T, Shimizu M, Okano K, et al. Intracellular signal transduction for interleukin-1 beta-induced endothelin production in human umbilical vein endothelial cells. Biochem Biophys Res Commun 1992;188:565-70.